Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
DXB0OP
|
||||
| Drug Name |
N-(4-(chlorodifluoromethoxy)phenyl)-5-(4-(2-(pyridin-4-yl)ethyl)pyridin-3-yl)-1,3,4-oxadiazol-2-amine
|
||||
| Synonyms |
CHEMBL382142
|
||||
| Indication | Discovery agent | Investigative | [1587926] | ||
| Formula |
C21H16ClF2N5O2
|
||||
| Canonical SMILES |
FC(F)(Cl)Oc1ccc(Nc2oc(nn2)c3cnccc3CCc4ccncc4)cc1
|
||||
| InChI |
InChI=1S/C21H16ClF2N5O2/c22-21(23,24)31-17-5-3-16(4-6-17)27-20-29-28-19(30-20)18-13-26-12-9-15(18)2-1-14-7-10-25-11-8-14/h3-13H,1-2H2,(H,27,29)
|
||||
| InChIKey |
GRYCCPMMCHYRGO-UHFFFAOYSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | [1587926] | ||
| Vascular endothelial growth factor receptor 1 | Target Info | [1587926] | |||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| VEGF signaling pathway | |||||
| Focal adhesion | |||||
| Proteoglycans in cancerhsa04014:Ras signaling pathway | |||||
| HIF-1 signaling pathway | |||||
| Transcriptional misregulation in cancer | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| VEGF signaling pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| Beta3 integrin cell surface interactions | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Notch-mediated HES/HEY networkglypican_1pathway:Glypican 1 network | |||||
| S1P3 pathway | |||||
| VEGFR1 specific signals | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.